Given this pivotal role, targeting SMAD3 presents a promising therapeutic strategy for managing DMD, as evidenced by research models showing reduced fibrosis and improved muscle functions upon modulation of this pathway (Zhou and Lu, 2010). This evidence concerns the gene SMAD3 and Duchenne muscular dystrophy.